Affichage 1 à 10 des 71 essais cliniques
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
ESSAIS CLINIQUES
    No essai
    ClinicalTrials.gov ID
Phase Coordonnateur(rice)
Essai randomisé portant sur la radiothérapie régionale pour le traitement du cancer du sein avec envahissement ganglionnaire à faible risque avec biomarqueur.
    MA.39
    NCT03488693
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Joshua Trivlidis
514-934-1934 poste 34909
Concordance entre la biopsie liquide et la biopsie tissulaire dans les cas de cancer du sein métastatique nouvellement diagnostiqué
    Concordance
    NCT04241237
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Neera Sriskandarajah
514-934-1934 poste 36686
(EN) A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
    lidERA Breast Cancer (GO42784)
    NCT04961996
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Stelliana Moreno
514-934-1934 poste 43131
(EN) A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
    TROPION-Breast04
    NCT06112379
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Anna Lysina
514-934-1934 poste 35391
(EN) A Randomized Trial of Five-Fraction Partial Breast Irradiation
    RAPID2
    NCT05417516
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Marianna Perna
514-934-1934 poste 43191
(EN) A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
    ASCENT-03
    NCT05382299
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Elsly Chen
514-934-1934 poste 35391
(EN) Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
    ELISA
    NCT04797299
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Marianna Perna
514-934-1934 poste 43191
(EN) RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
    BREVITY
    NCT03524430
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Fanie Bourgault
418-525-4444 poste 82697
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
    CAMBRIA-2
    NCT05952557
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Marie-Caude Lépine
418-525-4444 poste 82100
(EN) A Prospective Multi-center Clinical Study Evaluating the Use of PD G 506 A and the Eagle V1.2 Imaging System for the Visualization of Carcinoma During Breast Conserving Surgery
    SBI-CIP 20-002
    NCT04815083
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Marie-Caude Lépine
418-525-4444 poste 82100
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |